---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-354780"
form_type: "8-K"
ticker: "BMRN"
cik: "0001048477"
company_name: "BIOMARIN PHARMACEUTICAL INC"
filed_at: "2026-08-18T12:39:19+00:00"
generated_at: "2026-08-18T12:40:12.620949+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# BioMarin to acquire Alesta Therapeutics for $275M upfront plus $215M milestones

## Summary
- Upfront $275M cash plus up to $215M in development/regulatory milestone payments.
- Gains ALE1, potential first oral therapy for hypophosphatasia (HPP), in Phase 1/2a.
- Alesta spins out non-ALE1 assets and employees transfer to spinout before close.
- Expected to close Q3 2026; funded with cash on hand; modestly dilutive to 2026 results.
- BioMarin CEO cites strategic fit and larger rare disease market opportunity.

## SEC filing metadata
- accession: 0001193125-26-354780
- form_type: 8-K
- ticker: BMRN
- cik: 0001048477
- company_name: BIOMARIN PHARMACEUTICAL INC
- filed_at: 2026-08-18T12:39:19+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/0001193125-26-354780-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1048477/000119312526354780/d172628d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-354780
- JSON: https://secwatch.observer/filing/0001193125-26-354780.json
- Plain text: https://secwatch.observer/filing/0001193125-26-354780.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.